603739 蔚蓝生物
2026/06 - 中期
人民幣(K¥)
与去年同期
比较
2025/12
人民幣(K¥)
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
营业总收入709,6168.80%1,366,1241,320,7611,198,9021,163,163
减:营业总成本657,2627.48%1,281,2151,222,0061,093,8951,074,866
    其中:营业成本397,99511.10%754,152725,809644,687660,311
               财务费用9,76811.08%18,93820,77414,1825,276
               资产减值损失87-89.92%(6,526)(2,684)(6,519)(2,550)
公允价值变动收益6,09846.34%31,6448,3189,220212
投资收益1,091-962.44%(331)(1,239)6,4163,268
    其中:对联营企业和合营企业的投资收益(74)-57.71%(1,829)(8,487)(4,773)(1,641)
营业利润69,28328.42%127,592124,024122,901102,904
利润总额68,84129.71%123,706123,444122,495102,187
减:所得税费用15,50116.81%26,24031,27219,63816,776
净利润53,34034.00%97,46692,172102,85785,411
减:非控股权益14,78012.93%27,65629,53522,15015,569
股东净利润38,56044.33%69,81062,63780,70769,842

市场价值指针
每股收益 (元) *0.15036.36%0.2800.2500.3200.280
每股派息 (元) *----0.1000.1000.1000.100
每股净资产 (元) *7.0973.27%7.0456.8686.7516.515
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容